DDInter1042 DDInter385
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients.
Cisapride {u} (Compound) resembles {v} (Compound) Metoclopramide
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Iloperidone
Cisapride {u} (Compound) binds {v} (Gene) HTR2B
Cisapride {u} (Compound) upregulates {v} (Gene) PAK1
Cisapride {u} (Compound) downregulates {v} (Gene) PUF60
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Cisapride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Morphine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nevirapine
Cisapride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Cisapride {u} may lead to a major life threatening interaction when taken with {v} Haloperidol
Cisapride (Compound) resembles Metoclopramide (Compound)
Cisapride may lead to a major life threatening interaction when taken with Iloperidone
Cisapride (Compound) binds HTR2B (Gene)
Cisapride (Compound) upregulates PAK1 (Gene)
Cisapride (Compound) downregulates PUF60 (Gene)
Cisapride may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Cisapride may cause a minor interaction that can limit clinical effects when taken with Morphine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine
Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Cisapride may lead to a major life threatening interaction when taken with Haloperidol